Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope for RA patients: drug may heal bone erosion

NCT ID NCT05955066

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether baricitinib, a JAK inhibitor, can heal bone erosion in people with active rheumatoid arthritis. Sixty adults with moderate-to-severe RA and at least one bone erosion will receive either baricitinib or a placebo for 24 weeks. The main goal is to see if the drug reduces erosion size, measured by a special CT scan.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Baricitinib (Olumiant) 4 mg daily
What this could lead to
If successful, this could show that JAK inhibitors help repair bone damage in rheumatoid arthritis, potentially leading to better long-term joint health.
What could go wrong
This is a small, early-phase study with only 60 participants, so results may not apply to everyone. The treatment may not heal bone erosion, and JAK inhibitors carry risks like infections and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 year-old, 2. fulfilment of the 2010 ACR/EULAR classification criteria of RA, 3. on MTX for at least 12 weeks, and 4. disease activity score 28-C-reactive protein (DAS28-CRP) \> 3.2. Exclusion Criteria: 1. ≥65 years old, 2. functional status class IV (limited in ability to perform usual self-care, vocational, and avocational activities); 3. pregnancy or premenopausal women planning pregnancy; 4. ever use of any b/tsDMARDs or csDMARDs other than methotrexate and hydroxychloroquine for RA; 5. ever use of bisphosphonates, denosumab or teriparatide; 6. history of cardiovascular disease/thrombo-embolism/malignancy; 7. contraindications to baricitinib; and 8. severe joint damage in MCP2-4 which preludes HR-pqCT measurement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Chinese University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.